Protocol Ledger

NCT04401579 · Phase III · COMPLETED

Adaptive COVID-19 Treatment Trial 2 (ACTT-2)

Interventional Phase III clinical trial protocol NCT04401579 sponsored by National Institute of Allergy and Infectious Diseases (NIAID) in Infectious Disease and Vaccines, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2020-05-08 Enrollment: 1,033 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04401579
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)1,033 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04401579
Protocol FieldVerified Registry Value
NCT IdentifierNCT04401579
Consolidated Lead SponsorNational Institute of Allergy and Infectious Diseases (NIAID)
Therapeutic Condition CohortInfectious Disease and Vaccines
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment1,033 participants (ACTUAL)
Registered Start Date2020-05-08
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Infectious Disease and Vaccines Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI